阿帕替尼治疗化疗失败晚期肺腺癌的疗效观察

Efficacy of apatinib after failure of chemotherapy for advanced lung adenocarcinoma

目的探讨化疗失败的晚期肺腺癌患者采用阿帕替尼治疗的临床疗效。方法选取2019年1月至2020年12月间青岛阜外心血管病医院收治的100例化疗失败的晚期肺腺癌患者,采用系统抽样法分为观察组和对照组,每组50例。对照组患者采用常规营养对症支持治疗,观察组患者在对照组基础上采用阿帕替尼治疗,比较两组患者的临床疗效、不良反应发生率、生活质量及血清肿瘤标记物水平[癌胚抗原(CEA)、糖类抗原125(CA125)、CA199和神经元特异性烯醇化酶(NSE)]。结果观察组患者总控制率为76.0%,高于对照组的48.0%,差异有统计学意义(P<0.05)。观察组患者CEA、CA125、CA199和NSE肿瘤标记物水平均较对照组低,差异均有统计学意义(均P<0.05)。观察组患者高血压和蛋白尿发生率均较对照组高,眩晕发生率较对照组低,差异均有统计学意义(均P<0.05)。但患者均可耐受,未因严重不良反应中断治疗,且经对症处理后,均较好缓解。观察组患者生活质量评分均较对照组高,差异均有统计学意义(均P<0.05)。结论对化疗失败的晚期肺腺癌患者采用阿帕替尼治疗,可获取良好的临床疗效,不良反应可控制,安全性较高,且可有效改善生活质量。

Objective To explore the efficacy of apatinib in patients with advanced lung adenocarcinoma who failed chemotherapy.Methods A total of 100 patients with advanced lung adenocarcinoma who failed chemotherapy from January 2019 to December 2020 were enrolled.They were grouped into an observation group and a control group by systematic sampling with 50 patients in each group.Patients who received symptomatic and supportive treatment were included in the control group and patients who received apatinib besides symptomatic and supportive treatment were included in the observation group.Clinical efficacy,the incidence of adverse reactions,quality of life and the level of serum tumor markers including carcinoembryonic antigen(CEA),sugar chain sugar Original 125(CA125),sugar chain antigen 199(CA199)and serum neuron-specific enolase(NSE)were compared between the two groups.Results The overall disease control rate was 76.0%in the observation group which was higher than 48.0%of the control group.After treatment,the serum levels of CEA,CA125,CA199,and NSE tumor markers were lower in the study group than in the control group(all P<0.05).The incidence of hypertension and proteinuria was higher in the observation group than in the control group and the incidence of dizziness was lower in the observation group than in the control group(all P<0.05).However,all these adverse reactions were tolerable and were alleviated significantly after treatment and no patient discontinued the treatment because of them.Quality of life scores were higher in the observation group than in the control group(all P<0.05).Conclusion Apatinib can lead to good clinical efficacy and survival benefits in patients with advanced lung adenocarcinoma who have failed chemotherapy,and the adverse reactions are manageable,the safety is high,and quality of life is effectively improved.